Narayana's UK deal diluting profits. Northern expansion scrapped. Clinic losses flat.
Management admitted three prior assurances have broken. The UK acquisition is hitting EPS, clinic losses aren't falling, and the north India push is off.
— 6 earlier stories on Narayana Hrudayalaya Ltd. →What's new
- Clinic and insurance losses stayed flat at ₹66 cr for FY26, contradicting management guidance that they were declining.
- The UK acquisition is diluting consolidated PAT and return on equity, reversing prior EPS-neutral assurances.
- Capex was just ₹109 cr against a ₹424 cr budget; northern cluster expansion plans are scrapped.
Why this matters
Narayana's May concall is a litany of reversed guidance. Management had told investors clinic losses were narrowing, the UK deal wouldn't dilute earnings, and northern expansion was on track. None of those are now true. The India hospital EBITDA margin did expand 360 basis points to 25.1%, which is real progress. But the credibility gap between what was promised and what was delivered is the story here.
What we're watching
- Whether the UK deal will eventually deliver the promised EPS neutrality or remain a drag.
- If the unspent capex is redeployed or signals a structural shift in expansion strategy.
- How quickly clinic losses can actually be reduced now that the flat trajectory is acknowledged.
The full read
Narayana Hrudayalaya's May concall read like a mea culpa. Management admitted clinic losses stayed flat at ₹66 crore for FY26, reversing earlier guidance that they were falling. The UK acquisition is now actively diluting consolidated PAT and return on equity, a direct contradiction of the prior assurance that the deal would be earnings-per-share neutral. Northern cluster expansion is off the table entirely, with the company pivoting to south and east India. The capex miss was staggering: ₹109 crore spent against a ₹424 crore budget, a 74% shortfall management blamed on elections and labor shortages. The India hospital EBITDA margin did expand 360 basis points to 25.1%, driven by case complexity and payer mix. That's real operational progress. But it's overshadowed by the fact that three separate management assurances proved wrong in the same quarter. The credibility gap is now the primary overhang.
Questions answered
- Why did management's UK acquisition guidance prove wrong?
- The acquisition is diluting both consolidated PAT and return on equity. Management had previously assured investors the deal would be EPS-neutral.
- What happened to the northern expansion plan?
- Management scrapped it, pivoting focus to south and east India. The call cited election disruptions and labor shortages for the broader capex miss.
- How big was the capex shortfall?
- Narayana spent just ₹109 crore against a ₹424 crore budget for the year, missing its target by about 74%.
- Was any part of the financial performance positive?
- Yes, India hospital EBITDA margins expanded 360 basis points to 25.1%, driven by higher case complexity and better payer mix.
Story so far
All notes on NH →- 26 May 2026 · 4:26 PM IST Narayana's UK deal diluting profits. Northern expansion scrapped. Clinic losses flat.
- 1d ago Narayana Hrudayalaya's Q4 transcript adds no new data
- 12d ago Narayana Hrudayalaya clears FY26 results and debt plans
- 12d ago Narayana Hrudayalaya confirms FY26 numbers as expected
- 12d ago Narayana Hrudayalaya consolidated revenue jumps 44% on UK acquisition